Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia (PH94B-SAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01217788
Recruitment Status : Completed
First Posted : October 8, 2010
Last Update Posted : May 10, 2011
Information provided by:
Pherin Pharmaceuticals, Inc.

Brief Summary:
The purpose of this study is to determine the efficacy of PH94B, a new class of therapeutic compound, administered intranasally for the management of acute anxiety in patients diagnosed with generalized social phobia.

Condition or disease Intervention/treatment Phase
Social Phobia Social Anxiety Disorder Drug: PH94B intranasal spray Phase 2

Detailed Description:

The essential features of generalized social phobia are defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), criteria as a marked and persistent fear of most (generally accepted as four or more) social or performance situations in which the patient believes embarrassment could occur as a consequence of exposure to unfamiliar people and/or possible scrutiny by others. The anxiety resulting from the social or performance situation is profound. The avoidance, fear, or anxious anticipation of these situations interferes significantly with the person's daily routine, having a marked impact on occupational functioning and/or social life. The disorder has a lifetime prevalence estimated at up to 13%, with onset typically in the mid-teens, and it is diagnosed slightly more frequently in females than in males. Social phobia tends to be a chronic disorder with periods of exacerbation, with a reported mean duration of illness of approximately 20 years.

There are two subtypes of social phobia: (i) generalized (discrete), which is suffered by approximately 50% of social phobia patients and in which fear and avoidance extend to a wide range of social situations, and (ii) non-generalized, in which the patient fears only one or a few circumscribed situations. Speaking in front of large groups is by far the most prevalent of social fears (Lang and Stein, 2001).

Social phobia has a lifetime comorbidity rate of approximately 81% with other psychiatric disorders (particularly affective disorders, other anxiety disorders, and substance abuse disorders), as well as to being associated with increased nonpsychiatric medical difficulties. People with social phobia identify social impairment, inadequate social support, overall role impairment, specific impairment in education, work, and other activities, as well as interference in their efforts at self-improvement. Unfortunately, for these patients, there is a strong consensus that social phobia is one of the least commonly recognized and treated mental disorders

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Double Blind Placebo Controlled Study of PH94B for Management of the Symptoms of Generalized Social Phobia
Study Start Date : February 2008
Actual Primary Completion Date : February 2011
Actual Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety Phobias

Arm Intervention/treatment
Experimental: PH94B intranasal spray Drug: PH94B intranasal spray
Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray

Placebo Comparator: Placebo intranasal spray Drug: PH94B intranasal spray
Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray

Primary Outcome Measures :
  1. Subjective Unit of Discomfort Scale [ Time Frame: Once before and again 10 minutes after intranasal dosing with PH94B spray, during exposure to a public speaking challenge ]

Secondary Outcome Measures :
  1. Number of patients with adverse events as a measure of safety and tolerability on the psychometric scale [ Time Frame: Once at the end of the intervention and again one week after intervention (follow-up) ]
    One time after dosing and up to one week after dosing.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject currently meets the Diagnosis of Social Phobia as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition which is not secondary to another pre-existing psychiatric condition or to a medical condition.
  • Liebowitz Social Anxiety Scale (LSAS) score greater than or equal to 60 at Screening.
  • Score of 75 or greater on the SUD scale at one of the Performance Phase time points during either the Public Speaking or Social Interaction Challenge
  • Written Informed Consent prior to commencing any study specific procedures.
  • Women of child-bearing-potential must be able to commit to the consistent and correct use of an acceptable method of birth control throughout the study and have a negative serum pregnancy test result prior to study drug administration.

Exclusion Criteria:

  • Use of any psychotropic medication within 30 days prior to study entry.
  • Acute or chronic psychiatric disease which is the primary diagnosis (except Social Phobia) at the time of the study. Note that subjects with concurrent Generalized Anxiety Disorder (GAD) are allowed into the study provided this is not the primary diagnosis.
  • Subjects with a history of psychiatric diseases such as schizophrenia, bipolar disorder, and psychosis are to be excluded.
  • Presence of a clinical condition or disease, or use of a concomitant medication, that in the clinical judgment of the Investigator could place the patient at undue risk, interfere with study participation, or confound the results of the study.
  • Use of substances of abuse within the year prior to study entry.
  • Concomitant use of any over-the-counter, prescription product, or herbal preparation for treatment of the symptoms of social anxiety during the study and within 30 days prior to study entry and use of non-study anxiolytics such as benzodiazepines during the study and within 30 days prior to study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01217788

United States, New York
Medical Research Network
New York City, New York, United States, 10024
Sponsors and Collaborators
Pherin Pharmaceuticals, Inc.
Principal Investigator: Michael L Liebowitz, M.D. Medical Research Network

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Michael R. Liebowitz MD, The Medical Research Network LLC Identifier: NCT01217788     History of Changes
Other Study ID Numbers: PH94B CL022
First Posted: October 8, 2010    Key Record Dates
Last Update Posted: May 10, 2011
Last Verified: May 2011

Keywords provided by Pherin Pharmaceuticals, Inc.:
Generalized Social Phobia
Social Anxiety Disorder
Social Phobia
Phobic Disorders

Additional relevant MeSH terms:
Anxiety Disorders
Phobic Disorders
Phobia, Social
Mental Disorders